Remove en
article thumbnail

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

Fierce Pharma

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda aliu Thu, 03/23/2023 - 10:23

207
207
article thumbnail

ESMO: Roche's Alecensa staves off lung cancer recurrence en route to postsurgery expansion

Fierce Pharma

Moving drugs into early-stage cancers is in vogue these days. Moving drugs into early-stage cancers is in vogue these days. Roche has just posted a trial win for its targeted lung cancer therapy Alecensa that should enable earlier use, while eliciting a sense of déjà vu from a study of AstraZeneca’s Tagrisso.

156
156
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nordic Nanovector board resigns en masse as merger bid fails

pharmaphorum

The post Nordic Nanovector board resigns en masse as merger bid fails appeared first on. It is also running low on cash reserves, which were NOK 287 million (around $29 million) at the midpoint of the year and have been predicted to fall below NOK 100 million by the end of the year. Image by Alexander Fox | PlaNet Fox from Pixabay .

article thumbnail

Vertex scores double win with non-opioid pain drug

pharmaphorum

Vertex Pharma says its much-anticipated non-opioid painkiller, VX-548, clears two phase 3 trials en route to an FDA filing later this year

FDA 89
article thumbnail

Enterin and Parkinson’s UK to partner on dementia study

European Pharmaceutical Review

S) in the enteric nervous system (ENS) and central nervous system (CNS). S in the ENS and CNS, displacing and preventing aggregation, improving neural signalling of enteric neurons between the digestive system and brain via the vagus nerve. PD dementia (PDD) is largely caused by aggregation of the protein alpha-synuclein (?S)

article thumbnail

Roche Canada and pCPA conclude talks for Vabysmo eye therapy

Pharmaceutical Technology

Canada’s health technology assessment bodies, including the Canadian agency for drugs and technologies in health (CADTH) and the institut national d’excellence en santé et en services sociaux (INESSS) have both reviewed Vabysmo and recommended it to treat nAMD and DME.

Safety 52
article thumbnail

Digital Content Council on the Impetus InSite Platform®: A Customer Story

Impetus Digital

The client’s main objectives were to: En gag e headache specialists on a monthly basis to review marketing and patient education resources and drafts asynchronously. Leverage a variety of cutting-edge virtual tools to gather targeted and collaborative feedback and insights, while avoiding digital collaboration fatigue.